Literature DB >> 1732393

Radioiodine treatment of recurrent hyperthyroidism in patients previously treated for Graves' disease by subtotal thyroidectomy.

H Vestergaard1, P Laurberg.   

Abstract

Radioiodine therapy is often employed for treatment of patients with relapse of hyperthyroidism due to Graves' disease, after previous thyroid surgery. Little is known about the outcome of this treatment compared to patients with no previous surgery. A total of 20 patients who had received surgical treatment for Graves' hyperthyroidism 1-46 years previously and with relapse of the hyperthyroidism, and 25 patients with hyperthyroidism due to Graves' disease and no previous thyroid surgery were treated with radioiodine, following the same protocol. Early after treatment the previously operated patients showed a higher sensitivity to radioiodine, with more cases of early hypothyroidism, than non-operated patients. However, after 50 months of follow-up the outcome was identical. The results indicate that frequent assessment is necessary after radioiodine treatment of previously operated patients, since some patients develop early hypothyroidism.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1732393     DOI: 10.1111/j.1365-2796.1992.tb00492.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  3 in total

1.  Management of recurrent hyperthyroidism in patients with Graves' disease treated by subtotal thyroidectomy.

Authors:  K Sugino; T Mimura; O Ozaki; H Iwasaki; N Wada; A Matsumoto; K Ito
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

Review 2.  The role of surgery in primary hyperthyroidism.

Authors:  A P Weetman
Journal:  J R Soc Med       Date:  1998       Impact factor: 5.344

Review 3.  Hypothyroidism in the elderly: pathophysiology, diagnosis and treatment.

Authors:  Peter Laurberg; Stig Andersen; Inge Bülow Pedersen; Allan Carlé
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.